Skip to content

A (cost-) effectiveness of the anterior approach compared to the posterolateral approach for total hip arthroplasty

The anterior approach for total hip arthroplasty. A (cost-) effectiveness analysis compared to the posterolateral approach

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON26182
Enrollment
260
Registered
2015-04-12
Start date
2015-07-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary or secondary osteoarthritis of the hip

Interventions

Sponsors

Martini Hospital, Department of Orthopaedic Surgery
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age between 18 – 90 years; Indication for THA is primary or secondary symptomatic osteoarthritis.

Exclusion criteria

Exclusion criteria: A history of previous surgery on the ipsilateral hip;v complaints of the contralateral hip; a hip prosthesis at the contralateral side; symptomatic osteoarthritis of the knee; peripheral neuropathy; (active) arthritis (e.g. rheumatic disease); a history of CVA; COPD GOLD III or IV NYHA class III or IV cognitive impairments; not able to fill in questionnaires in the Dutch language.

Design outcomes

Primary

MeasureTime frame
Primary aim of this study is to assess the clinical effectiveness of the anterior approach compared to the conventional posterolateral approach, in terms of physical functioning and health-related quality of life.

Secondary

MeasureTime frame
To determine the effectiveness of the anterior approach on surgical outcome; To determine the effectiveness of the anterior approach on gait function; To determine the effectiveness of the anterior approach on social and work participation; To determine the cost-effectiveness of the anterior approach.

Contacts

Public ContactK. (Kyrill) Rykov

Department of Orthopaedics - Martini Hospital

Email: k.rykov@mzh.nlPhone: 050 524 59 70

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)